|
Sponsored by |
|---|
|
|
-
Need help navigating the forum? Find out how to use our features here.
-
Did you know we have lots of smilies for you to use?
Law Canada MJ News
- Thread starter Baron23
- Start date
just_tHe_fLu
they say im crazy but i have a good time
Killick
Well-Known Member
So 'legal' herb in Canada runs between $8 and $16 per gram. Craft growers charge around $90/oz. For those that are keeping up the 'legal' regime only allows dried herb, and also infused vegetable oil. If you happen to live near one of the few dispensaries then you'll have a better choice, but get there before the 'legal' regime shuts it down.
Canadians are also allowed 4 plants per residence. For those that want to control their own supply there's this guy... https://www.thegrowshow.ca/
https://www.cbc.ca/news/canada/edmonton/alberta-cannabis-home-grow-1.4810241
Canadians are also allowed 4 plants per residence. For those that want to control their own supply there's this guy... https://www.thegrowshow.ca/
https://www.cbc.ca/news/canada/edmonton/alberta-cannabis-home-grow-1.4810241
Last edited:
Bcbud
Cannabis enthusiast
It will be interesting with the upcoming addition of edibles/concentrates to the Canadian cannabis act.
From what I have read the excise tax on THC will be charged at .01 cents per mg based on the package size.
I have to figure out how they plan to handle CBD.
There has been some chatter that they will treat it as a health food supplement and allow it to be sold in health food stores.
From what I have read the excise tax on THC will be charged at .01 cents per mg based on the package size.
I have to figure out how they plan to handle CBD.
There has been some chatter that they will treat it as a health food supplement and allow it to be sold in health food stores.
Killick
Well-Known Member
@Bcbud I'm looking forward to edibles/concentrates being a big flop for the government revenue stream. They can't keep up to demand, it's almost impossible for rec users to purchase from the legal shops, and med patients are experiencing product shortages every day due to government legalization blunders.
Once people realize just how easy it is to transform plain herb into edibles/topicals/concentrates there isn't much requirement for the feds to figure out packaging or taxes. My medical plan currently provides my (dried herb and infused oils only), so a bunch of us have been teaching each other just how simple it is to make things.
A buddy recently obtained a hemp growing permit - he's allowed a plot that is 200m x 200m, and can process every part of the plant *except* the bud. Dropping buds on screens is hardly processing it, so thats where a great method for storing buds prior to 'disposing of them in an appropriate manner'...
Once people realize just how easy it is to transform plain herb into edibles/topicals/concentrates there isn't much requirement for the feds to figure out packaging or taxes. My medical plan currently provides my (dried herb and infused oils only), so a bunch of us have been teaching each other just how simple it is to make things.
A buddy recently obtained a hemp growing permit - he's allowed a plot that is 200m x 200m, and can process every part of the plant *except* the bud. Dropping buds on screens is hardly processing it, so thats where a great method for storing buds prior to 'disposing of them in an appropriate manner'...
Bcbud
Cannabis enthusiast
I have not yet had a need to experience the government offerings. I really enjoy the DYI aspects of cannabis.
My interest in concentrates is mainly for a source of strain specific rosin and extracts that have been tested for safety and purity.
I am looking into how I can go med as I have a qualifying condition but am uncomfortable about including my doctor in process.
My interest in concentrates is mainly for a source of strain specific rosin and extracts that have been tested for safety and purity.
I am looking into how I can go med as I have a qualifying condition but am uncomfortable about including my doctor in process.
Killick
Well-Known Member
Sent you a PM outlining how to become legal here in Canadia - it's a fairly simple process that isn't really advertised....
Genetically Modified Cannabis Is Coming To Canada: Avoid It By Getting Your License To Grow
Genetically Modified Foods have created a lot of fuss, they’re actually banned in a number of countries who have cited numerous environmental and health concerns. But what about Genetically Modified Weed? How do we know that the cannabis we are using here in Canada is clean and pure? How can we guarantee that it’s not full of toxic heavy metals. We recently published an article about marijuana testing labs caught approving contaminated weed for profit, you can read more about that here.
The point is, there are several great reasons to grow your own cannabis, growing for your own medicinal needs under Health Canada’s ACMPR program can be very rewarding and give you piece of mind knowing full well what chemicals and pesticides went into it.
Hyasynth Biologicals laboratory in Montreal currently has scientists working on genetically engineering the active ingredients in marijuana and then patenting them. They are part of multiple genetic engineering firms across Canada and the U.S., that’ve popped up over the past couple of years.
As CBC news reports, “Cannabis producers, biotech firms and drug companies, along with the law firms who represent them, say genetic engineering — a controversial technique pioneered in agriculture — will allow companies to patent genes synthesized from cannabis, potentially unlocking billions of dollars in new investment and creating jobs.”
This may be true, but people don’t really desire cannabis when it comes from drug companies, and other corporations they deem unethical.
Again, this is the primary reason why we encourage people to get their license so they can grow as much marijuana as they need. You’ll need a doctor to write you prescription that you feel you need, and we can connect you with these passionate doctors. So make sure you contact us for that. From here, using the proper Health Canada form found here, you will have to mail this document along with the ACMPR form found here which require you to specify where you plan to grow and you will also need the property owners consent if it is not your primary residence. We recommend always getting the property owners consent even if you don’t need it for this licence. If you’d like assistance to make sure you go through the process legally and the right way, please contact us about acquiring a licence and we’ll help you through the process every step of the way.
As far as the process for creating genetically altered versions of cannabis goes, scientists at Hyasynth Bio genetically alter fermented yeast — a process that’s similar to synthetic perfume from chemicals contained inside flowers — to construct copies of the DNA strands found in cannabis. The yeast acts like a small factory to produce cannabinoids in the lab.
Companies are obtaining patents for their yields, and there it’s currently a fight for dominance between companies to do this, including many pharmaceutical companies.
Can we really trust big pharma?
CBC news also points out that that some “cannabis companies aren’t so keen on the genetic engineering revolution. Bruce Linton, chief executive of Canopy Growth, one of Canada’s largest cannabis firms, told CBC his company has meet with half a dozen biotech experts who pitched them on genetic modification, but Canopy has stayed away from the technology.
“Our checklist includes not having a GMO as the base” of a product, Linton said.
With the industry just moving away from prohibition, throwing genetically altered cannabis strains into the mix is just a bridge too far for consumers right now, Linton said.
“People trust the plant as a source,” he said, while they might not be as comfortable with a product originating in a lab with genetically modified yeast. ”
At the end of the day, it’s best to just get your license and grow your own! Again, If you’d like assistance to make sure you go through the process legally and the right way, please contact us about acquiring a licence and we’ll help you through the process every step of the way.
Genetically Modified Foods have created a lot of fuss, they’re actually banned in a number of countries who have cited numerous environmental and health concerns. But what about Genetically Modified Weed? How do we know that the cannabis we are using here in Canada is clean and pure? How can we guarantee that it’s not full of toxic heavy metals. We recently published an article about marijuana testing labs caught approving contaminated weed for profit, you can read more about that here.
The point is, there are several great reasons to grow your own cannabis, growing for your own medicinal needs under Health Canada’s ACMPR program can be very rewarding and give you piece of mind knowing full well what chemicals and pesticides went into it.
Hyasynth Biologicals laboratory in Montreal currently has scientists working on genetically engineering the active ingredients in marijuana and then patenting them. They are part of multiple genetic engineering firms across Canada and the U.S., that’ve popped up over the past couple of years.
As CBC news reports, “Cannabis producers, biotech firms and drug companies, along with the law firms who represent them, say genetic engineering — a controversial technique pioneered in agriculture — will allow companies to patent genes synthesized from cannabis, potentially unlocking billions of dollars in new investment and creating jobs.”
This may be true, but people don’t really desire cannabis when it comes from drug companies, and other corporations they deem unethical.
Again, this is the primary reason why we encourage people to get their license so they can grow as much marijuana as they need. You’ll need a doctor to write you prescription that you feel you need, and we can connect you with these passionate doctors. So make sure you contact us for that. From here, using the proper Health Canada form found here, you will have to mail this document along with the ACMPR form found here which require you to specify where you plan to grow and you will also need the property owners consent if it is not your primary residence. We recommend always getting the property owners consent even if you don’t need it for this licence. If you’d like assistance to make sure you go through the process legally and the right way, please contact us about acquiring a licence and we’ll help you through the process every step of the way.
As far as the process for creating genetically altered versions of cannabis goes, scientists at Hyasynth Bio genetically alter fermented yeast — a process that’s similar to synthetic perfume from chemicals contained inside flowers — to construct copies of the DNA strands found in cannabis. The yeast acts like a small factory to produce cannabinoids in the lab.
Companies are obtaining patents for their yields, and there it’s currently a fight for dominance between companies to do this, including many pharmaceutical companies.
Can we really trust big pharma?
CBC news also points out that that some “cannabis companies aren’t so keen on the genetic engineering revolution. Bruce Linton, chief executive of Canopy Growth, one of Canada’s largest cannabis firms, told CBC his company has meet with half a dozen biotech experts who pitched them on genetic modification, but Canopy has stayed away from the technology.
“Our checklist includes not having a GMO as the base” of a product, Linton said.
With the industry just moving away from prohibition, throwing genetically altered cannabis strains into the mix is just a bridge too far for consumers right now, Linton said.
“People trust the plant as a source,” he said, while they might not be as comfortable with a product originating in a lab with genetically modified yeast. ”
At the end of the day, it’s best to just get your license and grow your own! Again, If you’d like assistance to make sure you go through the process legally and the right way, please contact us about acquiring a licence and we’ll help you through the process every step of the way.
Canadian pot producer Tilray to explore the use of cannabis for kids with aggressive behavioural problems in a new study
Researchers hope that if results show promise, CBD could someday potentially reduce or negate the use of drugs such as antipsychotics and antidepressants
Canadian LP giant Tilray has announced its involvement in a new Australian pilot study that explores the viability of a large-scale, placebo-controlled, randomized clinical trial of the use of a cannabis-derived compound for the treatment of aggressive behavioural problems in children with Intellectual Disabilities.
Led by the Murdoch Children’s Research Institute (MCRI) in Melbourne, Australia, the study includes 10 participants between the ages of eight and 16 who have a diagnosis of Intellectual Disability.
The “single site, double-blind, parallel group, randomized, placebo-controlled pilot study” will compare the results of administering CBD versus a placebo in the reduction of Severe Behavioural Problems.
Participants are given a placebo or Tilray’s C100 oral solution on a randomized basis. The solution contains cannabidiol (CBD), a psychoactive but non-intoxicating cannabinoid derived from the cannabis plant and often used in the treatment of afflictions such as anxiety, inflammation, and pain.
A worker holds a tray with cannabis cuttings at the new European production site of Tilray in Cantanhede, on April 24, 2018. PATRICIA DE MELO MOREIRA/AFP/GETTY IMAGES
Researchers hope that if results show promise, CBD could someday potentially reduce or negate the use of drugs such as antipsychotics and antidepressants, which can have serious side effects–especially in pediatric patients.
Led by the Murdoch Children’s Research Institute (MCRI) in Melbourne, Australia, the study includes 10 participants between the ages of eight and 16 who have a diagnosis of Intellectual Disability.
The “single site, double-blind, parallel group, randomized, placebo-controlled pilot study” will compare the results of administering CBD versus a placebo in the reduction of Severe Behavioural Problems.
Participants are given a placebo or Tilray’s C100 oral solution on a randomized basis. The solution contains cannabidiol (CBD), a psychoactive but non-intoxicating cannabinoid derived from the cannabis plant and often used in the treatment of afflictions such as anxiety, inflammation, and pain.
A worker holds a tray with cannabis cuttings at the new European production site of Tilray in Cantanhede, on April 24, 2018. PATRICIA DE MELO MOREIRA/AFP/GETTY IMAGES
Researchers hope that if results show promise, CBD could someday potentially reduce or negate the use of drugs such as antipsychotics and antidepressants, which can have serious side effects–especially in pediatric patients.
“We are committed to increasing the scientific understanding of cannabinoid-based medicine as a treatment for pediatric patients with intellectual disability and associated severe behavioral problems through this study,” Associate Professor Daryl Efron, MCRI senior researcher and pediatrician, said in a statement.
Tilray supplied the cannabis product to MCRI via its Good Manufacturing Practices facility in Nanaimo, B.C. earlier this year.
“We are committed to advancing cannabinoid-based science to further understand the potential benefits of medical cannabis as a treatment option among these critical patient populations,” said Philippe Lucas, VP of Global Patient Research and Access at Tilray. “There is a serious need for more clinical data in our field, and we are proud to support research like this around the world.”
The results of the trial are set to be published by 2020.
Researchers hope that if results show promise, CBD could someday potentially reduce or negate the use of drugs such as antipsychotics and antidepressants
Canadian LP giant Tilray has announced its involvement in a new Australian pilot study that explores the viability of a large-scale, placebo-controlled, randomized clinical trial of the use of a cannabis-derived compound for the treatment of aggressive behavioural problems in children with Intellectual Disabilities.
Led by the Murdoch Children’s Research Institute (MCRI) in Melbourne, Australia, the study includes 10 participants between the ages of eight and 16 who have a diagnosis of Intellectual Disability.
The “single site, double-blind, parallel group, randomized, placebo-controlled pilot study” will compare the results of administering CBD versus a placebo in the reduction of Severe Behavioural Problems.
Participants are given a placebo or Tilray’s C100 oral solution on a randomized basis. The solution contains cannabidiol (CBD), a psychoactive but non-intoxicating cannabinoid derived from the cannabis plant and often used in the treatment of afflictions such as anxiety, inflammation, and pain.
A worker holds a tray with cannabis cuttings at the new European production site of Tilray in Cantanhede, on April 24, 2018. PATRICIA DE MELO MOREIRA/AFP/GETTY IMAGES
Researchers hope that if results show promise, CBD could someday potentially reduce or negate the use of drugs such as antipsychotics and antidepressants, which can have serious side effects–especially in pediatric patients.
Led by the Murdoch Children’s Research Institute (MCRI) in Melbourne, Australia, the study includes 10 participants between the ages of eight and 16 who have a diagnosis of Intellectual Disability.
The “single site, double-blind, parallel group, randomized, placebo-controlled pilot study” will compare the results of administering CBD versus a placebo in the reduction of Severe Behavioural Problems.
Participants are given a placebo or Tilray’s C100 oral solution on a randomized basis. The solution contains cannabidiol (CBD), a psychoactive but non-intoxicating cannabinoid derived from the cannabis plant and often used in the treatment of afflictions such as anxiety, inflammation, and pain.
A worker holds a tray with cannabis cuttings at the new European production site of Tilray in Cantanhede, on April 24, 2018. PATRICIA DE MELO MOREIRA/AFP/GETTY IMAGES
Researchers hope that if results show promise, CBD could someday potentially reduce or negate the use of drugs such as antipsychotics and antidepressants, which can have serious side effects–especially in pediatric patients.
“We are committed to increasing the scientific understanding of cannabinoid-based medicine as a treatment for pediatric patients with intellectual disability and associated severe behavioral problems through this study,” Associate Professor Daryl Efron, MCRI senior researcher and pediatrician, said in a statement.
Tilray supplied the cannabis product to MCRI via its Good Manufacturing Practices facility in Nanaimo, B.C. earlier this year.
“We are committed to advancing cannabinoid-based science to further understand the potential benefits of medical cannabis as a treatment option among these critical patient populations,” said Philippe Lucas, VP of Global Patient Research and Access at Tilray. “There is a serious need for more clinical data in our field, and we are proud to support research like this around the world.”
The results of the trial are set to be published by 2020.
If cannabis is having any dire health effects, Canadian hospitals haven’t seen them
More than half a year in, Canada’s relaxed cannabis laws appear to be earning a clean bill of health from major medical organizations.
While many hard numbers on health shifts are not yet available, some of the country’s largest mental health and emergency centres say the new laws have dumped no discernible increase in cannabis-related cases on their doorsteps.
“It’s certainly something that we’re very concerned about and want to be watching for,” says Robert Mann, a senior scientist and impairment expert at Toronto’s Centre for Addiction and Mental Health. “But I’ve heard nothing — no indication that there’s all of a sudden a large increase.”
Mann says centre clinicians will routinely report on the cannabis habits of their patients, especially younger ones.
“When you start talking to clinicians they will say (that) a very large proportion of the young people that come to us are very much cannabis-engaged,” he says. “But over the last few months I’ve heard nothing about any kind of a big spike in the number of people coming in.”
Mann says the centre has long been tracking cannabis use and mental health issues among both youth and adults in the province, but that the latest, post-legalization data will not be released until early next year.
But in the lead-up to the new laws — which opened the recreational cannabis market last October — there were widespread fears that their health effects could be dire.
In a large Pollara Strategic Insights survey conducted in the months before legalization, for example, about 50 per cent of Canadians surveyed believed the laws would harm residents’ mental and physical well-being.
Those numbers declined to about 35 per cent in legalization’s wake. And the abating fears seem to be justified by observations from front-line emergency room workers who would typically deal first with pot-related maladies.
At Toronto’s University Health Network, the impact on the system’s two emergency departments has been imperceptible.
“We haven’t seen any difference,” says Dr. Sam Sabbah, director of emergency medicine at UHN, which operates ERs at its Toronto General and Toronto Western sites. “Cannabis was already very widespread so legalization has not had an appreciable increase in cannabis-related emergency department visits,” Sabbah said in an email.
The story has been much the same at St. Michael’s Hospital — one of the city’s two major trauma centres — where pot remains a distinctly secondary concern to alcohol.
“We do not have data on this, but anecdotally speaking we have not seen a significant increase in cases post-legalization,” says hospital spokesperson Michael Oliveira . “Alcohol-related injury … issues are far, far more common and can sometimes result in more serious, including critical, injuries.”
The paltry impact of legalized cannabis seen in Toronto ERs is being largely reflected across the country, says Dr. Atul Kapur, a spokesperson for the Canadian Association of Emergency Physicians.
An ER physician at the Ottawa Hospital, Kapur says the experience in places like Colorado — which legalized recreational cannabis in 2014 — had led Canadian doctors to believe the effects here would be minimal, and that has been the case. He says methamphetamines are a far more troubling and pressing concern in Canada’s emergency rooms.
Meanwhile, a federal report in April reported there were some 3,286 opioid-related deaths in Canada between January and September of last year.
However, Kapur says the scheduled legalization of edible cannabis products in October could change things, especially among children who could accidentally ingest the often tempting-looking confections.
“Even though edibles are not yet legal in Canada we’ve noticed a bit of an increase” in kids ingesting them, he says. “We’re worried that that is going to be an even worse problem when edibles become legalized.”
To this point, however, the Ontario Poison Centre — operated by Toronto’s Hospital for Sick Children — has seen no evidence of an increase in pot emergencies among children and teens, Dr. Margaret Thompson, the centre’s medical director said.
In a month-by-month breakdown from 2018, the centre recorded a high of 33 cannabis exposure cases in August, a month and a half before legalization, in kids younger than 19.
The centre, which also covers Manitoba and Nunavut, recorded just 16 cases in October, the month cannabis was legalized, 23 in November and 29 in December.
At CAMH, if further tracking does indeed show an increase in cannabis use among patients, Mann says it may well be attributable to a general rise in pot consumption — especially among adults — that began a decade ago.
“If there’s an increase that we see, it (will be) hard to say that it’s due to legalization because it’s been going up for 10 years,” he says.
Mann says that increase in pot consumption may be due to several factors, including a simple “cohort effect” that has seen the increased number of people who tried pot in their youth over recent decades still using into their adult and middle-aged years.
“It could (also) be due to the increased interest in medical cannabis,” he says. “People may be self-medicating for pain, anxiety, things like that.”
Mann does say, however, that the negative consequences of liberalized recreational cannabis laws seen in jurisdictions that passed them earlier in the decade have been mixed.
“There are some studies in some places reporting … increases in usage rates or maybe increases in the number of drivers that are found with cannabis in their system,” he says. “But it’s not been consistent across jurisdictions.”
Mann says it often takes years to detect the health and other impacts brought on by large-scale changes in drug laws.
For example, he says not much change in road safety was detected in the immediate wake of the drunk-driving laws that set blood alcohol limits at the familiar 0.08 in the late 1960s. But after a quarter-century of tracking, those cross-country laws were seen to have reduced impaired driving deaths by 17 per cent in Canada.
Emergency and cannabis industry experts have warned that pot-related ER visits may well spike among adults in October as well.
Inexperienced edibles users often overindulge — mistaking delayed highs for insufficient intakes and freaking out when the full impacts of the infused treats emerge.
While frightening, such overdoses virtually never prove fatal and the effect on an individual will almost always recede with time.
More than half a year in, Canada’s relaxed cannabis laws appear to be earning a clean bill of health from major medical organizations.
While many hard numbers on health shifts are not yet available, some of the country’s largest mental health and emergency centres say the new laws have dumped no discernible increase in cannabis-related cases on their doorsteps.
“It’s certainly something that we’re very concerned about and want to be watching for,” says Robert Mann, a senior scientist and impairment expert at Toronto’s Centre for Addiction and Mental Health. “But I’ve heard nothing — no indication that there’s all of a sudden a large increase.”
Mann says centre clinicians will routinely report on the cannabis habits of their patients, especially younger ones.
“When you start talking to clinicians they will say (that) a very large proportion of the young people that come to us are very much cannabis-engaged,” he says. “But over the last few months I’ve heard nothing about any kind of a big spike in the number of people coming in.”
Mann says the centre has long been tracking cannabis use and mental health issues among both youth and adults in the province, but that the latest, post-legalization data will not be released until early next year.
But in the lead-up to the new laws — which opened the recreational cannabis market last October — there were widespread fears that their health effects could be dire.
In a large Pollara Strategic Insights survey conducted in the months before legalization, for example, about 50 per cent of Canadians surveyed believed the laws would harm residents’ mental and physical well-being.
Those numbers declined to about 35 per cent in legalization’s wake. And the abating fears seem to be justified by observations from front-line emergency room workers who would typically deal first with pot-related maladies.
At Toronto’s University Health Network, the impact on the system’s two emergency departments has been imperceptible.
“We haven’t seen any difference,” says Dr. Sam Sabbah, director of emergency medicine at UHN, which operates ERs at its Toronto General and Toronto Western sites. “Cannabis was already very widespread so legalization has not had an appreciable increase in cannabis-related emergency department visits,” Sabbah said in an email.
The story has been much the same at St. Michael’s Hospital — one of the city’s two major trauma centres — where pot remains a distinctly secondary concern to alcohol.
“We do not have data on this, but anecdotally speaking we have not seen a significant increase in cases post-legalization,” says hospital spokesperson Michael Oliveira . “Alcohol-related injury … issues are far, far more common and can sometimes result in more serious, including critical, injuries.”
The paltry impact of legalized cannabis seen in Toronto ERs is being largely reflected across the country, says Dr. Atul Kapur, a spokesperson for the Canadian Association of Emergency Physicians.
An ER physician at the Ottawa Hospital, Kapur says the experience in places like Colorado — which legalized recreational cannabis in 2014 — had led Canadian doctors to believe the effects here would be minimal, and that has been the case. He says methamphetamines are a far more troubling and pressing concern in Canada’s emergency rooms.
Meanwhile, a federal report in April reported there were some 3,286 opioid-related deaths in Canada between January and September of last year.
However, Kapur says the scheduled legalization of edible cannabis products in October could change things, especially among children who could accidentally ingest the often tempting-looking confections.
“Even though edibles are not yet legal in Canada we’ve noticed a bit of an increase” in kids ingesting them, he says. “We’re worried that that is going to be an even worse problem when edibles become legalized.”
To this point, however, the Ontario Poison Centre — operated by Toronto’s Hospital for Sick Children — has seen no evidence of an increase in pot emergencies among children and teens, Dr. Margaret Thompson, the centre’s medical director said.
In a month-by-month breakdown from 2018, the centre recorded a high of 33 cannabis exposure cases in August, a month and a half before legalization, in kids younger than 19.
The centre, which also covers Manitoba and Nunavut, recorded just 16 cases in October, the month cannabis was legalized, 23 in November and 29 in December.
At CAMH, if further tracking does indeed show an increase in cannabis use among patients, Mann says it may well be attributable to a general rise in pot consumption — especially among adults — that began a decade ago.
“If there’s an increase that we see, it (will be) hard to say that it’s due to legalization because it’s been going up for 10 years,” he says.
Mann says that increase in pot consumption may be due to several factors, including a simple “cohort effect” that has seen the increased number of people who tried pot in their youth over recent decades still using into their adult and middle-aged years.
“It could (also) be due to the increased interest in medical cannabis,” he says. “People may be self-medicating for pain, anxiety, things like that.”
Mann does say, however, that the negative consequences of liberalized recreational cannabis laws seen in jurisdictions that passed them earlier in the decade have been mixed.
“There are some studies in some places reporting … increases in usage rates or maybe increases in the number of drivers that are found with cannabis in their system,” he says. “But it’s not been consistent across jurisdictions.”
Mann says it often takes years to detect the health and other impacts brought on by large-scale changes in drug laws.
For example, he says not much change in road safety was detected in the immediate wake of the drunk-driving laws that set blood alcohol limits at the familiar 0.08 in the late 1960s. But after a quarter-century of tracking, those cross-country laws were seen to have reduced impaired driving deaths by 17 per cent in Canada.
Emergency and cannabis industry experts have warned that pot-related ER visits may well spike among adults in October as well.
Inexperienced edibles users often overindulge — mistaking delayed highs for insufficient intakes and freaking out when the full impacts of the infused treats emerge.
While frightening, such overdoses virtually never prove fatal and the effect on an individual will almost always recede with time.
CarolKing
Always in search of the perfect vaporizer
Killick
Well-Known Member
Zerotol was just approved as another spray that can be applied to cannabis plants in Canada. For many of the approved sprays, Canada’s legal producers are actually allowed to follow a zero-day Pre-harvest interval (PHI,) meaning there is no required time between the last spray and actual harvest.
From the article:
Below is a list of cannabis sprays that have been discussed in this series so far, with the percentage of inert ingredients displayed:
Zerotol – 73% – For an oxidizing agent like Zerotol, unknown additives alongside just 5% peracetic acid boost the oxidative strength tenfold. Helping kill things even more efficiently.
Purespray Green Oil – 6% (alcohol ethoxylates/ethylene glycol)
Agrotek Sulphur – 0% (no inert ingredients).
Influence LC – 85%
Clyclone and Lactosan – 97%
https://cannabislifenetwork.com/cannabis-sprays-finding-formaldehyde-when-emulsifiers-burn/
From the article:
Below is a list of cannabis sprays that have been discussed in this series so far, with the percentage of inert ingredients displayed:
Zerotol – 73% – For an oxidizing agent like Zerotol, unknown additives alongside just 5% peracetic acid boost the oxidative strength tenfold. Helping kill things even more efficiently.
Purespray Green Oil – 6% (alcohol ethoxylates/ethylene glycol)
Agrotek Sulphur – 0% (no inert ingredients).
Influence LC – 85%
Clyclone and Lactosan – 97%
https://cannabislifenetwork.com/cannabis-sprays-finding-formaldehyde-when-emulsifiers-burn/
Baron23
Well-Known Member
Canopy Growth earnings show decline in recreational pot sales since launch of legal weed in Canada
Overall revenue gains, company says that marijuana production doubled in quarter and will double again this quarter
Canopy Growth stock tumbled over 7% Friday, a day after the world’s largest pot company reported that recreational pot sales in Canada declined from the previous quarter.
Canopy Growth Corp. CGC, -8.10% WEED, -7.42% reported Thursday fiscal fourth-quarter net losses of C$323.4 million ($245.2 million), or 98 cents a share, from a loss of C$54.4 million in the year-ago quarter. Much of that loss — more than C$130 million — was on paper, as Canopy had to account for the growth of its stock price in the first three months of the calendar year because of rules regarding the company’s convertible debt. Still, the company claimed an operational loss of C$174.5 million.
Revenue, net of excise taxes, rose to C$94.1 million from C$22.8 million in the year-ago period, and were up sequentially from C$83 million in the third quarter. According to FactSet, analysts on average modeled losses of C$95.2 million, or 25 cents a share. Net of excise taxes, analysts expected Canopy Growth to bank C$90.6 million in fourth-quarter revenue.
TimeCanopy Growth Corp.Aug 18Oct 18Dec 18Feb 19Apr 19Jun 19
US:CGC
$20$30$40$50$60
While overall revenue gained from the fiscal third quarter, when marijuana was officially legalized in Canada, recreational sales did not. Canopy said it took in C$68.9 million in the quarter from sales of recreational pot, down from C$71.6 million the quarter before, when legal sales began two weeks into the quarter.
When asked in the conference call Friday about the sequential decline, Canopy Growth co-Chief Executive Bruce Linton said that was a result of both the company’s production in prior quarters and the fact that bricks-and-mortar retail is slow to open in provinces such as Alberta and Ontario.
“Obviously when Alberta needed to pause, in their opinion, the additional licensing of stores and Ontario got going in April, that kind of made the platform static,” Linton said in the conference call. “What we’re seeing is a lot more stores opening obviously in Alberta and we’re seeing quite a bit more discussion and rumor about whether Ontario will do some more sooner. So the channel is growing.”
Also read: Canopy Growth’s quiet co-CEO on the pot company’s ambitions in the U.S. and more
In its announcement, the company stated that it was still ramping production of cannabis to meet demand, with harvest size doubling in its fiscal fourth quarter — the first calendar quarter — and expected to double again in the current quarter. Canopy claimed a gain of more than C$77 million in biological assets, or marijuana that was produced in the quarter but not sold, which boosts the bottom line.
Executives said Friday in the conference call they expect a fiscal first quarter harvest of 34,000 kilograms that will largely be sold in the second and third quarters. Linton said in the call that he expects about half the provinces will be able to launch edible products immediately on Dec. 16 when sales are set to begin, adding that the private companies involved are reacting more quickly than the government-run stores. Linton also said that the company believes it can hit a C$1 billion revenue “run rate” by fiscal fourth quarter 2020, that will mostly arrive from Canada sales.
Chief Financial Officer Mike Lee, who joined Canopy Growth from Constellation Brands Inc.’s STZ, -1.63% said in the conference call that he plans to implement several changes to the company’s accounting policies. Executives said Canopy planned to issue segmented revenue in the future, are moving the company’s accounting policies to U.S.-generally accepted accounting principals and will attempt to integrate acquisitions more quickly, among other things.
Canopy announced results just minutes before after-hours trading closed in the U.S., and shares closed the extended session up 0.7%. The stock plunged more than 7% in morning trading Friday. The U.S.-listed stock ended the regular session Thursday up 2.2% at $43.71, which gave the company a market capitalization of $15.1 billion in U.S. dollars. Shares have gained 62.7% so far this year, as the S&P 500 index SPX, -0.02% has increased 17.8%.
In April, Canopy Growth said that it planned to pay Acreage Holdings Inc. shareholders $300 million for the right to acquire Acreage in the future for $3.4 billion in stock. Shareholders from both companies approved the transaction Wednesday. Canopy has said it plans to license several of its brands to Acreage for the American market.
Part of the reason Canopy Growth was able to make such a substantial investment in the U.S. — at a time when American multistate cannabis companies are unable to easily access cash — is Constellation Brands’ $4 billion investment in the company. Constellation said Friday that it’s share of Canopy Growth’s fourth-quarter losses was $106 million, or $78.2 million after including tax benefits.
“If they didn’t have the cash then it would be unlikely they could do such a deal as it would be very difficult to raise capital in the debt markets for a right to buy when that rights not even certain anytime soon,” Jefferies analysts Owen Bennett wrote in a note to clients when the deal was announced.
For more: In ‘the marijuana ghetto’ at Davos, Canopy Growth found its American pot partner
Canopy Growth has been touting its investments in its U.S. hemp and cannabidiol, or CBD, operations since the farm bill passed last year. On Wednesday the company said that it has hemp or CBD operations in seven states with a full capacity of 4,000 acres. Currently, it is planing high-CBD hemp plants and industrialized hemp plants suitable for textiles, proteins and bioplastics.
In the conference call, CEO Linton said that in the long run, Canopy Growth will have the capacity to use its hemp facilities to grow and process marijuana once it’s legalized under U.S. federal law. For its current hemp and CBD operations, Lindon said that there are a number of states that will allow a “full spectrum” of CBD products including drinks, edibles — so long as Canopy doesn’t make health claims.
Overall revenue gains, company says that marijuana production doubled in quarter and will double again this quarter
Canopy Growth stock tumbled over 7% Friday, a day after the world’s largest pot company reported that recreational pot sales in Canada declined from the previous quarter.
Canopy Growth Corp. CGC, -8.10% WEED, -7.42% reported Thursday fiscal fourth-quarter net losses of C$323.4 million ($245.2 million), or 98 cents a share, from a loss of C$54.4 million in the year-ago quarter. Much of that loss — more than C$130 million — was on paper, as Canopy had to account for the growth of its stock price in the first three months of the calendar year because of rules regarding the company’s convertible debt. Still, the company claimed an operational loss of C$174.5 million.
Revenue, net of excise taxes, rose to C$94.1 million from C$22.8 million in the year-ago period, and were up sequentially from C$83 million in the third quarter. According to FactSet, analysts on average modeled losses of C$95.2 million, or 25 cents a share. Net of excise taxes, analysts expected Canopy Growth to bank C$90.6 million in fourth-quarter revenue.
TimeCanopy Growth Corp.Aug 18Oct 18Dec 18Feb 19Apr 19Jun 19
US:CGC
$20$30$40$50$60
While overall revenue gained from the fiscal third quarter, when marijuana was officially legalized in Canada, recreational sales did not. Canopy said it took in C$68.9 million in the quarter from sales of recreational pot, down from C$71.6 million the quarter before, when legal sales began two weeks into the quarter.
When asked in the conference call Friday about the sequential decline, Canopy Growth co-Chief Executive Bruce Linton said that was a result of both the company’s production in prior quarters and the fact that bricks-and-mortar retail is slow to open in provinces such as Alberta and Ontario.
“Obviously when Alberta needed to pause, in their opinion, the additional licensing of stores and Ontario got going in April, that kind of made the platform static,” Linton said in the conference call. “What we’re seeing is a lot more stores opening obviously in Alberta and we’re seeing quite a bit more discussion and rumor about whether Ontario will do some more sooner. So the channel is growing.”
Also read: Canopy Growth’s quiet co-CEO on the pot company’s ambitions in the U.S. and more
In its announcement, the company stated that it was still ramping production of cannabis to meet demand, with harvest size doubling in its fiscal fourth quarter — the first calendar quarter — and expected to double again in the current quarter. Canopy claimed a gain of more than C$77 million in biological assets, or marijuana that was produced in the quarter but not sold, which boosts the bottom line.
Executives said Friday in the conference call they expect a fiscal first quarter harvest of 34,000 kilograms that will largely be sold in the second and third quarters. Linton said in the call that he expects about half the provinces will be able to launch edible products immediately on Dec. 16 when sales are set to begin, adding that the private companies involved are reacting more quickly than the government-run stores. Linton also said that the company believes it can hit a C$1 billion revenue “run rate” by fiscal fourth quarter 2020, that will mostly arrive from Canada sales.
Chief Financial Officer Mike Lee, who joined Canopy Growth from Constellation Brands Inc.’s STZ, -1.63% said in the conference call that he plans to implement several changes to the company’s accounting policies. Executives said Canopy planned to issue segmented revenue in the future, are moving the company’s accounting policies to U.S.-generally accepted accounting principals and will attempt to integrate acquisitions more quickly, among other things.
Canopy announced results just minutes before after-hours trading closed in the U.S., and shares closed the extended session up 0.7%. The stock plunged more than 7% in morning trading Friday. The U.S.-listed stock ended the regular session Thursday up 2.2% at $43.71, which gave the company a market capitalization of $15.1 billion in U.S. dollars. Shares have gained 62.7% so far this year, as the S&P 500 index SPX, -0.02% has increased 17.8%.
In April, Canopy Growth said that it planned to pay Acreage Holdings Inc. shareholders $300 million for the right to acquire Acreage in the future for $3.4 billion in stock. Shareholders from both companies approved the transaction Wednesday. Canopy has said it plans to license several of its brands to Acreage for the American market.
Part of the reason Canopy Growth was able to make such a substantial investment in the U.S. — at a time when American multistate cannabis companies are unable to easily access cash — is Constellation Brands’ $4 billion investment in the company. Constellation said Friday that it’s share of Canopy Growth’s fourth-quarter losses was $106 million, or $78.2 million after including tax benefits.
“If they didn’t have the cash then it would be unlikely they could do such a deal as it would be very difficult to raise capital in the debt markets for a right to buy when that rights not even certain anytime soon,” Jefferies analysts Owen Bennett wrote in a note to clients when the deal was announced.
For more: In ‘the marijuana ghetto’ at Davos, Canopy Growth found its American pot partner
Canopy Growth has been touting its investments in its U.S. hemp and cannabidiol, or CBD, operations since the farm bill passed last year. On Wednesday the company said that it has hemp or CBD operations in seven states with a full capacity of 4,000 acres. Currently, it is planing high-CBD hemp plants and industrialized hemp plants suitable for textiles, proteins and bioplastics.
In the conference call, CEO Linton said that in the long run, Canopy Growth will have the capacity to use its hemp facilities to grow and process marijuana once it’s legalized under U.S. federal law. For its current hemp and CBD operations, Lindon said that there are a number of states that will allow a “full spectrum” of CBD products including drinks, edibles — so long as Canopy doesn’t make health claims.
Bcbud
Cannabis enthusiast
https://beta.canada.com/news/politi...wcm/d7820fe2-f7b2-4a14-a523-49370eff4aec/amp/
Speaks for its self.
Speaks for its self.
Canada passes law to speed pardons for pot possession
The new bill is aimed at shedding the "burden of stigma"
TORONTO — The Canadian government passed a law late on Wednesday that would allow its citizens with a criminal record for marijuana possession to be pardoned without any cost and expedite a process that previously could take up a decade.
The new bill is aimed at shedding the “burden of stigma” and removing barriers for employment, education, housing, volunteering and travel for people with a record for simple possession of cannabis, Senator Tony Dean said in a statement.
The bill titled C-93 follows Canada’s legalization of the sale and recreational use of marijuana and cannabis products last year, making Canada the first industrialized nation to legalize recreational cannabis.
Out of 54,940 cases of cannabis-related offenses, 76% were for simple possession in 2016, according to Statistics Canada.
The new bill is expected to speed the pardon process by eliminating the potential five- to 10-year wait time and waives an application fee of CA$631 ($479).
It calls for a “simplified and expedited version” of the pardon process, and will be allowed as long as the sentence had been completed and if the only conviction on their criminal record was for simple marijuana possession.
The new bill is aimed at shedding the "burden of stigma"
TORONTO — The Canadian government passed a law late on Wednesday that would allow its citizens with a criminal record for marijuana possession to be pardoned without any cost and expedite a process that previously could take up a decade.
The new bill is aimed at shedding the “burden of stigma” and removing barriers for employment, education, housing, volunteering and travel for people with a record for simple possession of cannabis, Senator Tony Dean said in a statement.
The bill titled C-93 follows Canada’s legalization of the sale and recreational use of marijuana and cannabis products last year, making Canada the first industrialized nation to legalize recreational cannabis.
Out of 54,940 cases of cannabis-related offenses, 76% were for simple possession in 2016, according to Statistics Canada.
The new bill is expected to speed the pardon process by eliminating the potential five- to 10-year wait time and waives an application fee of CA$631 ($479).
It calls for a “simplified and expedited version” of the pardon process, and will be allowed as long as the sentence had been completed and if the only conviction on their criminal record was for simple marijuana possession.
Baron23
Well-Known Member
That's really fucked up and contributes to my ever building contempt for government as it exists today.
I mean, they are fucking the Indians so that they, the government, can open its own store in the prime location of this city. That is so messed up.
So, the USA is probably the most litigious place in the world, but don't these tribes have some avenue for relief through the courts?
Bcbud
Cannabis enthusiast
It’s pretty fucked up but minor compared to the senseless incarceration of cannabis users in parts of the USA ,
Cannabis-lookalike found in Ontario contains carfentanil
Canadian health officials issued a public alert concerning a drug that looks dangerously similar to cannabis. However, this drug contains opioids [1].
The Waterloo Region Integrated Drug Strategy stated in a press release that the drug substance has been discovered in Ontario, Canada. It is reported to look like cannabis, but a test found that it contained no ‘weed’ at all.
Instead, the test showed the substance contained carfentanil. Guelph police testify this cannabis lookalike has not been found there or in the Waterloo Region. Officials are still confirming where in Ontario the substance has been found.
“Be aware that opioids (carfentanil, fentanyl) cannot be detected by sight, smell, or taste,” the press release reads. “Overdose can occur via inhalation, ingesting or injecting.”
Guelph police Const. Mike Gatto says that although the cannabis look-alike has not been found in Guelph or the Waterloo region, it’s important for everyone to be aware of this situation. Contamination with these synthetic opioids can happen anywhere as a similar product was recently found in Ohio containing both fentanyl and heroin.
Fentanyl and carfentanil are no joke. They are hundreds to thousands of times more potent than heroin or morphine, which increases the risk of overdose. According to the CDC, “During July 2016–June 2017, among 11,045 opioid overdose deaths, 2,275 (20.6%) decedents tested positive for any fentanyl analog, and 1,236 (11.2%) tested positive for carfentanil” [2]
A Case of Two Teenagers Overdosing
Last week, two teens, ages 16 and 18, smoked what they thought was cannabis, but they ended up losing consciousness and experiencing seizures. A neighbor noticed the situation and called 911 around 2 p.m. [3]
The Halton Regional officers who arrived treated the teens with naloxone to reverse the effects of the unknown substance, which they suspected to be an opioid overdose.
Police are still investigating what drugs exactly the teenagers were smoking, but they suspect it may be this cannabis look-alike.
The Issue of Mixing Drugs
Legalizing marijuana in Canada for recreational use was intended to halter the illegal black market. However, illegal drug dealers like to find ways to enhance their products. It seems what is selling best for them are opioids, like heroin and the even more dangerous fentanyl, and carfentanil.
Previously, officials were on the search for heroin laced with fentanyl, but now it is being laced with marijuana. This creates an intense and very addictive high, which can also be fatal.
“Carfentanil, fentanyl seems to be mixing into everything,” said Gatto. “Anything from the street is certainly dangerous. The only way to be even somewhat safe is by legal means.”
The police suspect the substance is purposely produced to appear like pot so it won’t be seized, due to the law in Canada that reads a person can have 30 grams of marijuana in his or her possession.
“If you have a bag that looks like that, someone will think it’s cannabis and not think it’s fentanyl on first look,” said Staff Sgt. Brenna Bonn, head of drugs for Waterloo Regional Police.
Recognizing Opioid Overdose
It can be difficult to differentiate when a person is very high on opioids or experiencing an overdose. In times of doubt, it is safer to treat these circumstances like an overdose. This could save a life.
If you are concerned about someone is becoming too high, it’s important not to leave them alone. If they are still conscious, help them walk around, keep them awake, and monitor their breathing.
Symptoms of someone high on ‘downers’ like heroin include:
- Small, contracted pupils
- Muscles are slack
- Tend to “nod out”
- Constant scratching because of itchy skin
- Slurred speech
- While they may act out of it, they still respond to a stimulus like a loud noise or a light shake.
- Loss of consciousness
- Unresponsive to an outside stimulus
- Awake, but cannot talk
- Breathing has become slow, shallow, erratic, or stopped
- The skin turns bluish purple, or grayish and ashen, depending on the skin tone
- Vomiting
- Choking sounds, or a snore-like gargling noise
- Limp body
- Pale and clammy face
- Fingernails and lips become blue or purplish black
- Pulse is slow, erratic, or has stopped [4]
If you or someone you know overdoses:
- Call 911 immediately.
- Check the breathing and heart rate.
- If there is no breathing, turn the person on their side.
- Find out as much as possible about the dose and the last time the drug was used.
- If the person is conscious, talk to them to assess their level of alertness and keep them engaged and awake if possible.
- Administer naloxone if the overdose is from opioids.
- Do not administer stimulants.
- Assist and keep the victim company until paramedics arrive. [5]
Baron23
Well-Known Member
CannTrust vows to take 'appropriate actions' to restore trust
CannTrust Holdings Inc. (TRST.TO 1.66%) confirmed that it filed a response to Health Canada last week, after the Vaughan, Ont.-based pot firm was found to be non-compliant with certain regulations at one of its facilities in Ontario.
In a release Monday, CannTrust said it filed a report to the regulator July 17, that its special committee’s investigations and deliberations are ongoing, and the company will take “appropriate actions” to address its compliance culture and restore trust.
"The special Committee takes these issues very seriously and is committed to working with Health Canada to bring the company into compliance,” said Robert Marcovitch, chairman of the special committee appointed by CannTrust’s board of directors to investigate the situation, in the release.
CannTrust announced on July 11 it was suspending all sales and shipments following a Health Canada inspection that discovered thousands of kilograms of cannabis believed to have been grown over a six-month period in unlicensed rooms.
The company’s deadline to respond to Health Canada’s audit was last Thursday at midnight.
CannTrust Holdings Inc. (TRST.TO 1.66%) confirmed that it filed a response to Health Canada last week, after the Vaughan, Ont.-based pot firm was found to be non-compliant with certain regulations at one of its facilities in Ontario.
In a release Monday, CannTrust said it filed a report to the regulator July 17, that its special committee’s investigations and deliberations are ongoing, and the company will take “appropriate actions” to address its compliance culture and restore trust.
"The special Committee takes these issues very seriously and is committed to working with Health Canada to bring the company into compliance,” said Robert Marcovitch, chairman of the special committee appointed by CannTrust’s board of directors to investigate the situation, in the release.
CannTrust announced on July 11 it was suspending all sales and shipments following a Health Canada inspection that discovered thousands of kilograms of cannabis believed to have been grown over a six-month period in unlicensed rooms.
The company’s deadline to respond to Health Canada’s audit was last Thursday at midnight.
|
Sponsored by |
|---|
|
|
|